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Abstract
Obesity is known to cause physical and metabolic diseases. It is often assumed 
by people (including the healthcare workers) that the person with obesity lacks self-
control in matters of diet and physical exercise, and is therefore responsible for his 
or her weight. Persons with obesity have to face sarcasm, barbs, and discrimination 
due to their condition. They often have difficulty in getting jobs or have to accept 
lower than standard pay for their work. Although weight gain requires calorie intake 
in excess of calorie expenditure, it is sometimes not easy for the person to restrict 
calories due to the underlying causes of obesity. The body resists losing weight, and 
attempts to hoard calories by reducing the metabolic rate. In this chapter we have 
explained and classified the causes of obesity into endogenous and exogenous. The 
endogenous causes include genetic and epigenetic causes, maternal factors, and 
hormonal causes, while exogenous causes include obesogenic environment, life-
style, and weight-gain promoting medicines. It must be realized that losing weight 
and keeping it off is not easy for a person with obesity.
Keywords: Obesity, Endocrine causes of obesity, Endogenous causes of obesity, 
Exogenous causes of obesity, Genetics of obesity
1. Introduction
Calorie intake that exceeds body requirements results in storage of the excess 
calories in the body. Although proteins are highly versatile in function, they cannot 
be used to store excess energy. The amount of glycogen that can be stored in adult 
liver is 100–120 grams, the skeletal muscle can store about 400 gram glycogen in 
a 70 kg adult. Small amounts are also present in other cells. The triacylglycerols 
(TAGs) are the best suited for energy storage purpose: they are energy-dense, 
hydrophobic (therefore do not associate with space-filling calorie empty water 
molecules), and can be stored in huge amounts. However, excess storage of the 
TAGs is often associated with ailments and early mortality. The Obesity Medicine 
Association has defined obesity as a ‘chronic, relapsing, multi-factorial, neu-
robehavioral disease, wherein an increase in body fat promotes adipose tissue 
dysfunction and abnormal fat mass physical forces, resulting in adverse metabolic, 
biomechanical, and psychosocial health consequences’ [1]. Since measurement of 
body fat content is tedious and requires sophisticated instruments, it is easier to 
define overweight and obesity on the basis of the Body Mass Index (BMI). BMI is 
calculated easily by dividing the weight of the person in kilograms by the square 
of height in meters. According to the World Health Organization, persons with 
BMI <  18.5 kg/m2 are underweight, those with BMI 18.5 to < 25 kg/m2 fare of 
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normal weight, those with BMI 25 to < 30 kg/m2 are overweight, and those with 
BMI > 30 kg/m2 are obese [2]. Besides affecting the patient on the individual level 
(posing increased risk of obesity-related diseases), obesity affects families and 
nations in terms of healthcare requirements, reduced working capacity, and eco-
nomic burden. Annual healthcare costs for obesity exceed $700 billion [3]. With the 
global increase in the incidence of obesity and obesity-related diseases, healthcare 
costs for obesity have exceeded those for smoking [4].
Thermodynamics can explain the excess storage of TAGs in a simple, succinct 
manner: storage of calories occurs when calorie intake exceeds calorie expendi-
ture. Decreasing the intake and increasing the expenditure should melt away the 
excess fat. Research conducted in the past 70 years reveals that adipose tissue that 
has grown out of size wants more of itself and persuades the body to devise ways 
to hoard calories. Thus, obesity is not merely a case of poor self-control. Also, all 
persons with obesity do not develop obesity-related diseases, as the type of adipose 
tissue and the site of deposition influence the risks to health.
2. Identifying obesity and determining the adipose content
The fact that weight is related to longevity of the person was realized by life 
insurance companies [5]. A higher health risk was predicted for weight more than 
20% the ideal weight for that height. This is equivalent to a BMI of 27.8 kg/m2. BMI 
cannot differentiate muscle from fat, or inform about the distribution of fat. It can-
not detect changes in body composition due to sarcopenia or osteopenia. It has been 
observed that some races are at a higher risk of type 2 diabetes mellitus and cardio-
vascular diseases at BMI values lower than what are normal for persons of European 
descent. Distribution of body fat is different in different races, Asians tend to have 
more central adiposity compared to the Caucasians [6]. Males have higher lean mass 
and bone mineral mass compared to females, however, females have more periph-
eral distribution of fat [7]. Pregnancy, age, and menopause cause redistribution of 
body fat, promoting central obesity [8]. It is important to determine the fat content 
of the body as well as the distribution of the body fat. The best method for deter-
mining fat content and fat distribution is cadaver analysis, as no in vivo technique 
can be that accurate [9].
Anthropometric methods are the most convenient and most popular for estimat-
ing the extent of fatness. Besides BMI, these include waist and hip circumferences, 
waist-to-hip ratio (WHR), skin fold thickness, and waist-to stature ratio (WSR). 
Since shorter individuals usually weigh less, weight alone cannot be used as a crite-
rion to determine the amount of fat stores. WSR and waist circumference are easy 
and relatively accurate techniques to estimate visceral fat [10]. The body adiposity 
index (BAI) does not require weight measurement; it is the ratio of hip circumfer-
ence to height. It is a fairly accurate measure of adiposity and can be easily used in 
remote areas without accessibility to reliable scales [11].
According to the two compartment (2C) model, the mass of the human body can 
be categorized into anhydrous Fat Mass (FM) and Fat Free Mass (FFM). The FFM 
includes water, minerals, and proteins. FM is assumed to have a density of 0.9007 g/
cm3 while the FFM is assumed to have a density of 1.1000 g/cm3. Water content of 
the body is assumed to be 73.72% [12]. Techniques based on two-component model 
are bioelectric impedance analysis, whole body counting of total body potassium, 
densitometry methods (hydrostatic underwater weighing and air displacement 
plethysmography), and hydrometry using isotope dilution technique. The water 
content (hydration fraction), bone mineral content, and density of the FFM vary 
with age, pubertal status, and pregnancy. These values are altered in patients with 
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deranged hydration and in those who have recently lost weight. Differences related 
to ethnicities have also been observed.
In the 3 compartment (3C) model of body composition assessment, the FFM is 
sub-divided into lean tissue mass (LTM) and bone mineral content (BMC). This 
method requires densitometry as well as hydrometry measurements and includes 
dual energy X-ray absorptiometry (DEXA), a rapid non-invasive method for 
regional as well as whole body measurement in which high- and low-energy X-rays 
are transmitted through the body.
The 4 compartment model further categorizes LTM into total body water 
(TBW) and protein. It requires a combination of several measurement techniques: 
hydrodensitometry like under-water weighing or air-displacement plethysmog-
raphy (to measure fat), DEXA (to measure mineral), isotope dilution (to measure 
water), and residual techniques (to measure protein) [13, 14]. It is an expensive, 
elaborate, and time requiring technique.
Multi-component models have also been used that incorporate results from 
many techniques, and are therefore more accurate. Simple methods can be used in 
the field, while lab-based methods or CT, MRI, X-ray techniques can be used only in 
clinical settings.
Anthropometric methods and bioelectric impedance analysis are considered 
indirect methods of assessment. Direct methods include measurement of total body 
water by isotope dilution technique, total body counting to measure radioactive 
potassium, and neutron activation techniques with a body scan to measure different 
elements. Criterion methods include underwater weighing, air-displacement pleth-
ysmography, DEXA, computed tomography (CT) scan, and magnetic resonance 
imaging (MRI) [15].
Vague in 1947 [16] noted that pear-shaped body with higher fat distribution 
in hips and thigh regions is associated with protection against metabolic diseases. 
Deposition of fat in the abdominal region (usually seen in males) is associated 
with development of metabolic diseases [17, 18]. Most of the adipose tissue in the 
adult human is white adipose tissue (WAT), the main function of which is to store 
excess calories as triacylglycerols. The brown adipose tissue (BAT), present in small 
quantities in the interscapular region, is responsible for non-shivering thermogen-
esis. WAT present in visceral regions is called visceral adipose tissue (VAT), and that 
present below the skin for insulation is called subcutaneous adipose tissue (SAT). 
Excess VAT is associated with the metabolic complications of obesity, like metabolic 
syndrome, type 2 diabetes mellitus, dyslipidemia, and cardiovascular diseases. 
TAGs may deposit in tissues other than the adipose; this is called ectopic fat. Ectopic 
fat in viscera, heart, and vasculature can be seen in lipodystrophy, characterized by 
little subcutaneous fat and high amounts of ectopic fat. Deposition of thoracic peri-
aortic fat and peripheral artery disease is considered local toxic effect of the ectopic 
fat. The renal sinus fat has been associated with hypertension and chronic kidney 
disease [19]. Although BMI is the most common method to identify overweight and 
obesity, it is unable to differentiate VAT and SAT, and central and global obesity. CT 
and MRI can be used to quantify the amount of visceral fat accurately. DEXA can 
also be used, however, it tends to underestimate VAT in people with normal BMI, 
and overestimates VAT in people with severe obesity [20].
It has been noted that some individuals classified as overweight or obese accord-
ing to their BMI do not show insulin resistance or increased risk of metabolic 
diseases. Such people are said to have metabolically healthy obesity (MHO), which 
can be a transient stage of variable duration that progresses towards metabolically 
unhealthy obesity (MUO) [21]. A person with obesity can be classified as metaboli-
cally healthy if blood pressure, blood glucose, TAG, and high density lipoprotein 
cholesterol levels are normal without medication [22]. Metabolically unhealthy 
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obesity results when adipocytes of SAT are unable to proliferate and differenti-
ate. Such tissue shows hypertrophy instead of hyperplasia, leading to ectopic and 
visceral deposition of fat.
3. What causes overweight and obesity?
The imbalance between energy intake and expenditure can result from vari-
ous causes that can be broadly classified into endogenous and exogeneous. In his 
paper on obesity, Pennington has described how the concept of endogenous obesity 
originated in 1907 [23].
3.1 Endogenous causes of obesity
Genetic and epigenetic disorders, hormonal imbalances, maternal and birth-
related factors, microbiome, and infections are included in the endogenous causes 
of obesity. In case of children, pathologic cause can be suspected if the patient 
shows hyperphagia with absence of satiety signals, shows food-seeking behavior, 
hides or steals food, has neuroendocrine abnormalities, has skin and hair that are 
lighter than those of siblings, or is gaining weight rapidly before the age of 5 years.
3.1.1 Genetic causes of obesity
Ethnic differences in obesity have been observed; admixture mapping studies 
show that obesity correlates with percentage of ancestry derived from ethnic groups 
[24]. Studies on individual families and animal models revealed rare obesity causing 
genes like leptin and leptin receptor genes, melanocortin 4 receptor gene, and the 
proopiomelanocortin genes, etc. Studies on obesity concordant monozygotic twins 
show BMI and other anthropometric measures like WHR are 40–60% heritable in 
children and adults [25]. The genome-wide association studies (GWAS) using mas-
sive study populations identified 119 independent loci associated with BMI [26]. 
The human obesity gene map discussed by Rankinen et al. [27] lists single-gene 
mutations in 11 different genes, 50 loci related to Mendelian syndromic obesity, 253 
quantitative trace loci (QTL) for obesity-related phenotypes. On the basis of clinical 
presentations, genetic obesity can be classified into monogenic non-syndromic, 
monogenic syndromic, and polygenic obesity.
A. Non-syndromic monogenic obesity. Rare, early-onset severe obesity that 
is mainly caused by mutations in genes whose products are involved in the regula-
tion of food intake. Most mutations require two dysfunctional copies of genes as 
homozygous or compound heterozygous condition in order to affect the phenotype. 
Around 200 single gene mutations have been associated with human obesity, but all 
are confined to more than 10 genes.
1. Leptin. The name leptin has been derived from the Greek word ‘leptos’ which 
means ‘thin’. Leptin (product of ob or LEP gene) is a 167 amino acid protein 
synthesized mainly in the adipocytes and enterocytes, and also in gastric 
epithelium and placenta. It is also called the satiety hormone as it regulates fat 
stores by diminishing hunger. Since its discovery in 1994 [28], leptin has been 
considered a potential target in the treatment of obesity.
Mutations in leptin gene are very rare, lead to hyperphagia and obesity, 
and can be ameliorated by leptin administration [29]. Administration of 
exogenous leptin reduces hyperphagia that is spontaneous or induced by 
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fasting [30]; chronic administration causes weight loss by reducing food 
intake [31, 32]. In most persons with obesity, circulating leptin levels are 
high, indicating that leptin resistance rather than leptin deficiency is the 
underlying reason for weight gain.
2. Leptin receptor. Multiple isoforms of leptin receptor (Ob-R or LEPR) have 
been identified, which are produced by alternative splicing of the mRNA or by 
post-translational modifications [33]. Ob-Rb, the long form of leptin recep-
tor expressed widely in the hypothalamus and appetite-modulating pathways 
of brain stem, has an intracellular domain that binds Janus kinases (JAK) and 
signal transducers and activators of transcription (STAT)-3 factors [34, 35]. 
The activated JAK–STAT-3 pathway induces expression of suppressor of cyto-
kine signaling (SOCS)-3. SOCS are a family of eight proteins that negatively 
regulate the JAK–STAT pathway, i.e., the very pathway that increases their 
synthesis.
Obesity-related leptin-resistance may be due to overexpression of the SOCS-3. 
This has been supported by the fact that SOCS-3 deletion in specific neurons 
in mice [36] or mice with heterozygous global SOCS-3 deficiency [37, 38] are 
more leptin-sensitive and resistant to weight gain. Ob-Rb, the long form of 
leptin receptor, is expressed in the arcuate nucleus of the hypothalamus in 
two neuronal groups: orexigenic neurons expressing neuropeptide (NP)Y 
and agouti-related peptide (AgRP), and by anorexigenic neurons expressing 
proopiomelanocortin (POMC) and cocaine-amphetamine-regulated transcript 
(CART) [39]. Leptin inhibits the expression of the orexigenic peptides NPY 
and AgRP, and activates the neurons producing the anorexigenic peptides 
POMC and CART [40, 41], thus reducing food intake. Low circulating levels of 
leptin lead to increased expression of NPY and AgRP, decreased expression of 
POMC and CART, and increased hunger. High levels of leptin in blood de-
crease the expression of NPY and AgRP, increase the expression of POMC and 
CART, and decrease hunger. Viral-mediated gene expression used to produce 
chronic leptin overexpression in the arcuate and paraventricular nuclei and 
ventromedial hypothalamus resulted in reduced food intake [42].
The secretory isoform of the leptin receptor binds circulating leptin and modu-
lates its biologic availability, while the short isoform of the leptin receptor is 
involved in the transport of leptin across the blood–brain barrier [43]. Leptin 
resistance may be due to defect in leptin receptor, or in the transport of leptin 
across the blood–brain barrier. Such persons have early-onset obesity and 
hypogonadism, however, the obesity is not as severe as in the case of persons 
lacking plasma leptin [42]. In rodents, a high-fat diet produces leptin resis-
tance, prior to the weight gain [43].
Mutations in leptin receptor gene (LEPR) produce a phenotype similar to that 
of leptin deficiency, with normal or high leptin levels [44, 45]. Often, LEPR 
mutations are accompanied with deficiencies of growth hormone or thyroid 
hormone [46, 47].
3. Proopiomelanocortin. The precursor protein pre-proopiomelanocortin is a 
267 amino acid protein synthesized in the corticotrophs and melanotrophs 
of the anterior and intermediate lobes of the pituitary [48]. A 26 amino acid 
signal peptide is removed to form proopiomelanocortin (POMC) with 241 
amino acids. Cleavage of POMC forms multiple peptide hormones (α-, β-, and 
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γ-melanocyte stimulating hormones (MSH), adrenocorticotropic hormone 
(ACTH), and β-endorphin). The cleavage is brought about by pro-hormone 
convertase (PC)1/3 (encoded by PCSK 1 gene in humans), carboxypeptidase 
(CP) E, and other enzymes. Mutations in PCSK1 and CPE are known to cause 
monogenic obesities (discussed later). The peptide products are packaged into 
vesicles and released by exocytosis. The processed products of POMC bind to 
different types of melanocortin receptors (MCRs), and to the μ-opioid recep-
tor [49]. Five MCRs (MC1R to MC5R) have been identified on the basis of their 
binding properties and tissue locations. MC1R is mainly located on the mela-
nocytes of skin and preferentially binds α-MSH. ACTH can also bind to MC1R. 
When ACTH is present at high concentrations, as in Cushing’s disease, it can 
cause hyperpigmentation. MC2R is mainly expressed in the adrenal cortex, and 
binds only ACTH to activate glucocorticoid synthesis. MC3R binds α-, β-and 
γ-MSH with equal affinity, is present on POMC neurons in the arcuate nucleus, 
and acts as an inhibitory auto-receptor. MC4R has a very high expression in the 
paraventricular nucleus of the hypothalamus and is involved in energy balance 
(discussed later). The primary agonist for MC4R is α-MSH released from the 
anorexigenic POMC neurons in the paraventricular nucleus. The primary antag-
onist of this receptor is agouti-related protein AgRP), released by the orexigenic 
AgRP/NPY neurons, also located in the paraventricular nucleus. MC5R is not 
expressed in the central nervous system. It is expressed in a variety of periph-
eral tissues during embryogenesis and binds with α-MSH with a slightly higher 
affinity. The μ-opioid receptor is expressed in the cortex, hippocampus, and 
brain stem, and in peripheral tissues. It binds β-endorphin mediating analgesic 
effect, and is also involved in feeding behavior.
Mutations in the POMC gene are autosomal recessive and cause early-onset 
severe obesity accompanied by hyperphagia, adrenal insufficiency, mild hy-
pothyroidism, and red/ginger hair [50]. Very few patients with this condition 
have been diagnosed worldwide. Heterozygous individuals have intermediate 
increase in BMI.
4. Prohormone convertase 1 and carboxypeptidase E. Prohormone convertase 
(PC1/3), also called PCSK1 (pro-protein convertase subtilisin/kexin type 1), 
is present only in neuroendocrine cells and is involved in the conversion of 
prohormones to active hormones. It is a serine protease, activated by calcium. 
CPE, also called enkephalin convertase, releases terminal arginine or lysine 
residues from polypeptides. It is involved in the production of nearly all neuro-
peptides and peptide hormones.
Mutations in PC1/3 gene are extremely rare [51] and cause severe obesity in 
childhood. Since this enzyme is involved in the maturation of many hormones, 
its deficiency is also associated with adrenal, gonadotropic, somatotropic, and 
thyrotropic insufficiency and postprandial insulin deficiency. Proinsulin levels 
are high. Patients have severe malabsorptive neonatal diarrhea and may show 
central diabetes insipidus.
Only a few patients with CPE mutations have been identified throughout the 
world. Such patients have morbid obesity, intellectual disability, type 2 diabe-
tes, and hypogonadotropic hypogonadism [52].
5. Melanocortin 4 receptor. This is encoded by the MC4R, an intron-less gene 
with open reading frame of 999 bp located on chromosome 18. The MC4R is 
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glycosylated and has 332 amino acids. It is mainly expressed by brain cells and 
by the enteroendocrine cells. Besides the neurons, it is also expressed by the 
astrocytes in brain [53].
The MC4R plays a key role in weight regulation. It is activated by α-MSH, and 
cocaine- and amphetamine-regulated transcript (CART) to decrease food 
intake and increase energy expenditure. The orexigenic peptides neuropeptide 
Y (NPY) and AgRP are the natural antagonists of MC4R, and increase appetite 
and reduce energy expenditure by binding to MC4R [54]. Leptin stimulates the 
secretion of POMC, and inhibits that of AgRP and NPY.
Heterozygous mutations in MC4R gene reported in different ethnic groups 
are associated with dominantly inherited obesity. MC4R deficiency is the 
commonest monogenic cause of obesity. In a cohort of 500 children with obe-
sity, 5.8% were found to have mutations in the MC4R gene [55]. Homozygous 
mutations and double heterozygous mutations are rare; about 25% mutations 
are heterozygous frame shift or nonsense with complete loss of function. 
Around 20% of the missense mutations are non-pathogenic. Heterozygous 
carriers of MC4R mutations have hyperphagia, impaired satiety, hyperin-
sulinemia, higher bone mineral density, and higher stature (big boned), 
especially in childhood. Patients homozygous for the condition have severe 
obesity and hyperinsulinemia which can be blocked by the administration of 
an α-adrenergic blocker. The hyperinsulinemia shows an age-related decrease 
and parallels amelioration of hyperphagia. Adults with MC4R deficiency 
have lower blood pressure and heart rate than age and BMI matched controls 
suggesting impaired activation of sympathetic nervous system. Diet-induced 
weight loss is not easy, but can be achieved by bariatric surgery in hetero-
zygous persons. Liraglutide promotes weight loss in patients with MC4R 
deficiency.
6. Single-Minded Homolog 1 (SIM1). The single-minded (sim) is a basic helix–
loop–helix-PAS domain transcription factor in Drosophila melanogaster that 
regulates gene expression in midline cells in the embryo [56]. SIM1, the human 
homolog, may have pleiotropic effects during embryogenesis. The SIM1 gene is 
located on chromosome 6; chromosomal abnormalities like deletion of 6q16.2 
region, translocation between 6q16.2 and 1p22.1, or point mutations in the 
6q16.2 region cause severe childhood obesity or SIM1-related Prader-Willi-like 
syndrome. Homozygous SIM1 knockout mice do not survive due to absence of 
hypothalamic neurons [57].
7. Brain Derived Neurotrophic Factor (BDNF). BDNF, also called neurotrophin 
and abrineurin, is encoded by the BDNF gene on human chromosome 11 [58]. 
The BDNF preproprotein with 247 amino acid residues is processed to mature 
119 amino acid protein. Pro-BDNF can be stored in dendrites and axons and 
undergoes cleavage either inside or outside the cell. BDNF and pro-BDNF are 
associated with opposing functions. High levels of BDNF are present in the 
hippocampus, amygdala, cerebellum, and cerebral cortex. Lower levels have 
been detected in the liver, heart, lung, etc. BDNF is a member of the neuro-
trophin family of growth factors required for the differentiation, maturation, 
and survival of neurons. In adverse conditions like hypoglycemia, cerebral 
ischemia, neurotoxicity, and glutamatergic stimulation, BDNF has a neuro-
protective effect. It is also involved in plastic changes related to learning and 
memory [59].
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Receptors for BDNF include TrkB, encoded by the NTRK2 gene, and LNGFR 
(low affinity nerve growth factor receptor). The TrkB receptor belongs to the 
family of tyrosine kinase receptors and is coupled to the Ras, Cdc42/Rac/
RhoG, MAPK, PI3K, and PLC-γ signaling pathways. Binding of BDNF with 
TrkB causes autophosphorylation of TrkB and is important for the develop-
ment of short term memory and growth of neurons. LNGFR is also called p75. 
Pro-BDNF preferentially binds to LNGFR, leading to NFκB receptor activa-
tion, triggering apoptosis pathway.
WAGR syndrome involves disorders of many body systems and is named for 
its main features: Wilms tumor (a childhood kidney cancer), aniridia, genito-
urinary anomalies, and intellectual disability (formerly referred to as mental 
retardation). A subtype of the WAGR syndrome called WAGRO (characterized 
by childhood onset obesity) has been reported to be strongly associated with 
haploinsufficiency for BDNF [60]. Nineteen patients with deletions in any por-
tion of the BDNF gene were reported to become obese by 10 years of age.
8. NTRK2. The NTRK2 gene encodes TrkB receptor for BDNF. In case of mice, 
homologous NTRK2 mutations are lethal. Heterozygous missense mutations 
in NTRK2 have been reported in patients with severe hyperphagia, obesity, 
impaired nociception, and intellectual disability [61].
9. Kinase Suppressor of Ras 2. This protein is a molecular scaffold that coor-
dinates Raf/MEK/ERK signaling and regulates activation of AMP-kinase. It 
is a product of KSR2 or the Fat gene located on chromosome 12q. Both KSR 1 
and KSR2 phosphorylate Raf, MEK, and ERF at several serine and threonine 
residues and cause their activation [62]. On stimulation by growth factor, the 
KSR proteins translocate to the plasma membrane to regulate the dynamics of 
Ras–Raf–MEK signaling.
Targeted deletion of Ksr2 in mice leads to obesity with hyperinsulinemia and 
low glucose tolerance.
10. SH2B Adaptor Protein 1. The Src homology 2b family members are adap-
tor proteins for several members of the tyrosine kinase receptor family. They 
contain SH2 and PH domains and can form homo or hetero dimers via their 
N-terminal dimerization domains. The SH2 domain present on the C-terminus 
binds proteins phosphorylated at their tyrosine residues: TrkA, insulin recep-
tors, IGF2-receptors, insulin receptor substrate (IRS)-1 and 2, and JAK2 [63].
The SH2B1 is a product of the SH2B1 gene located on chromosome 16p. It 
stimulates JAK2 activity and assembles JAK2/IRS1/2 complex to enhance leptin 
signaling. It also enhances catalytic activity of insulin receptor and protects 
IRS from dephosphorylation, thus increasing insulin signaling. Deletion of 
SH2B1 in mice leads to leptin resistance, hyperphagia, obesity, insulin resis-
tance, and type 2 diabetes.
Several SH2B1 mutations have been associated with obesity in humans and 
are known to increase the risk of type 2 diabetes mellitus. Partial deletions 
of about 200 bp are associated with early-onset severe obesity, while larger 
interspersed deletion extending through a 593 kb region on chromosome 
16p11.2-p12.2 has been associated with developmental delay, feeding difficul-
ties, dysmorphic facial features, and obesity [64].
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11. Adiponectin. This 244 amino acid protein is also called adipocyte comple-
ment-related protein (Acrp), GBP-28, apM1, and adipo Q [65]. The ADIPOQ 
gene is present on chromosome 3. This hormone is produced mainly by the 
adipocytes and also by other tissues like osteoblasts, liver, myocytes, epithelial 
cells, and placenta. It is secreted as trimer, (67 kDa, also called low molecu-
lar weight or LMW), hexamer, and a multimer with at least 18 monomers 
(300 kDa, high molecular weight or HMW). Globular adiponectin is generated 
from full length adiponectin by proteolysis. Plasma levels of adiponectin are 
inversely proportional to the amount of adipose. Adiponectin levels are high 
after weight loss due to calorie restriction or gastric bypass surgery in patients 
with obesity [66, 67], and also in patients anorexia nervosa [68].
Administration of adiponectin to rodents, and transgenic mice with increased 
adiponectin showed increased energy expenditure and oxygen consumption 
without affecting food intake [69, 70]. Adiponectin has been shown to sup-
press obesity [71], insulin resistance, type 2 diabetes [72, 73], atherosclerosis, 
and non-alcoholic fatty liver disease [74].
Adiponectin receptor AdipoR1 is more in the skeletal muscle, and AdipoR2 is 
more in the liver. Expression of receptors is proportional to insulin levels, and 
in case of receptors on the muscle cells, the number is increased with exercise 
[75]. AdipoR1 has a higher affinity for globular adiponectin while AdipoR2 has 
higher affinity for full length adiponectin. The T-cadherin receptor for adipo-
nectin recognizes hexameric and HMW forms of adiponectin. It is present in 
the vasculature and is involved in the cardioprotective action of adiponectin. 
Action of adiponectin on receptor requires adaptor proteins APPL1 or its iso-
form APPL2.
Binding of adiponectin to its receptor leads to activation of the AMP-activated 
protein kinase (AMPK) and the mitogen-activated protein kinase (MAPK). 
This causes increased NO production, adiponectin-induced glucose uptake, 
degradation of ceramide by ceramidase, and fatty acid oxidation, ultimately 
increasing insulin sensitivity.
Adiponectin deficiency has been associated with increased atherosclerosis 
while increased expression of adiponectin protects against atherosclerosis in 
mice [76]. Thiazolidinediones (TZD) used in the treatment of type 2 diabetes 
mellitus, are known to activate transcription factor peroxisome proliferator-
activated receptor (PPAR)-γ, which has been shown to increase adiponectin 
levels in plasma [77].
Adiponectin mutations have been associated with type 2 diabetes mellitus [78] 
and hypoadiponectinemia [79]. Recently, mutation in ADIPOQ has been as-
sociated with early-onset obesity and metabolic syndrome [80].
12. Adenylate Cyclase Type 3. Adenylate cyclase type 3 belongs to the adenyl-
ate cyclase family of enzymes that synthesize cAMP from ATP. The gene for 
this enzyme ADCY3 is located on chromosome 2 and codes for a 1144 amino 
acid protein. The protein shows highest expression in lungs and placenta, 
intermediate expression in brain, heart, kidney, and skeletal muscle. Low-
est expression is seen in liver and pancreas. It is also present in the olfactory 
cilia. Saeed et al. [81] reported loss-of-function mutations in ADCY3 gene in 
4 severely obese children from 3 consanguineous Pakistani families, and in 
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an obese boy from a non-consanguineous European American family. Inter-
estingly, a gain-of-function mutation in ADCY3 gene in a line of N-ethyl-N-
nitrosourea (ENU)-mutagenized mice, Jll, with dominantly inherited resis-
tance to diet-induced obesity, protects mice from diet-induced obesity [82].
13. Other Monogenic Causes of Obesity. Mutations in the INSIG2 gene [83, 84] 
and in gene for peroxisome proliferator-activated receptor gamma (PPAR-γ) 
[85, 86] are associated with obesity. INSIG2 gene present on chromosome 2 en-
codes for insulin-induced gene 2 protein which is involved in lipid homeosta-
sis. The gene for PPAR-γ (PPARG), present on chromosome 3p, can be activat-
ed by fatty acids and their metabolites. The protein is produced predominantly 
in liver and adipose and is crucial for the differentiation of fat cells. Besides 
obesity, mutations in this gene can cause insulin resistance, hypertension, and 
certain cancers.
Insulin-sensitizing drugs thiazolidinediones are potent agonists of PPAR-γ. 
This can also lead to increased adiponectin levels (see above).
B. Syndromic Obesity. Patients with obesity (children or adults) who also show 
cognitive delay, dysmorphic features, organ-specific abnormalities, hyperphagia, 
and/or signs of hypothalamic dysfunction are considered to have syndromic 
obesity. Syndromic obesity may show autosomal or X-linked inheritance pattern, 
or may occur due to de novo mutations. Since comorbidities are present that require 
additional treatment, it is important to correctly diagnose syndromic obesity, which 
can be of the following types:
1. Fat Mass and Obesity-Associated Protein (FTO) or Alpha-Ketoglutarate-
Dependent Dioxygenase Deficiency. This enzyme is coded by the FTO gene 
located on chromosome 16 in humans. The FTO proteins participate in adi-
pogenesis and tumorigenesis and FTO inhibitors have been found to have 
anti-obesity and anti-cancer effects in vivo. FTO is one of the genes known 
to contribute to polygenic obesity. In fact, it was the first one to be identi-
fied by genome wide association studies (GWAS) [87]. In humans, complete 
deficiency of FTO is associated with an autosomal recessive syndrome with 
growth retardation, malformations, and premature death. A loss-of-function 
non-synonymous mutation at position 316 in the FTO gene in which arginine 
is replaced by glutamine has been identified in nine members of a Palestinian 
family. The afflicted members showed post-natal growth retardation, dysmor-
phism of head and face, psychomotor delay, and in some patients, brain, car-
diac, genital, and palate defects. Complete/partial inactivation of FTO gene in 
mice protects from obesity while overexpression leads to increased food intake 
and obesity. Evidence suggests that certain mutations of FTO may increase the 
risk of obesity in humans.
2. Prader-Willi syndrome (PWS). This is caused by loss-of-function mutation of 
specific genes on chromosome 15 [88]. In most cases, a part of chromosome 15 
from the father is deleted. In some cases, the patient lacks father’s chromosome 
15 and has two copies from the mother. Some parts of the mother’s chromo-
somes are turned off by imprinting. This is usually not an inherited condition 
and affects 1 in 10,000 to 1 in 25,000 neonates. Polyhydramnios, reduced fetal 
movements, and abnormal fetal position may be present. New born may have 
hypogonadism, lethargy, poor muscle tone and difficulty in feeding. Afflicted 
children show delayed milestones, short stature, poor physical coordination, 
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crossed eyes. Hyperphagia begins between the ages of two and eight years 
and continues throughout life. The child gains excess weight. Adults with this 
condition have central obesity, hypogonadism, infertility, subnormal intelli-
gence, extreme flexibility, and light skin and hair. More than 50% patients have 
strabismus.
3. Bardet-Biedl syndrome (BBS). This is a rare pleiotropic, autosomal recessive 
ciliopathy, the estimated incidence is 1 in 1,60,000 in north European popula-
tions [89]. About 16 genes are associated with this disorder, accounting for 
80% cases. Diagnosis is based on clinical features: post-axial polydactyly, renal 
dysfunction, obesity, retinal dystrophy, hypogonadism, and learning dif-
ficulties.
The BBS phenotype is less apparent in the first decade of life and the condition 
is usually diagnosed in late childhood or early adulthood.
4. Alstrom syndrome (ALMS). This is also called Alstrom-Halgren Syndrome 
[90]. It is a very rare autosomal recessive disorder due to defect in the ALMS1 
gene located on chromosome 2p13. The encoded protein is implicated in ciliary 
function, control of cell cycle, and intracellular transport. About 900 people 
with this syndrome have been reported worldwide. This syndrome is charac-
terized by childhood obesity (but normal birth weight), hyperphagia, hyper-
insulinemia, and type 2 diabetes mellitus. Other features include progressive 
cone-rod dystrophy leading to blindness (occurring usually prior to 15 months 
of age) and sensorineural hearing loss (usually bilateral, beginning in the first 
decade of life). Otitis media with glue ear has been reported. About 70% patients 
develop dilated cardiomyopathy during infancy or adolescence. Renal failure, 
pulmonary, hepatic, and urologic dysfunction are often observed, and systemic 
fibrosis develops with age. Unlike the Bardet-Biedl syndrome, there is no men-
tal defect, polydactyly, or hypogonadism. Retinal lesion causes nystagmus and 
early loss of central vision in contrast to loss of peripheral vision first, as in other 
pigmentary retinopathies. Height is normal or more than normal in children, but 
growth slows down so that adults are usually of short stature. The symptoms and 
rate of progression of disease varies in patients, even amongst members of the 
same family.
5. Pseudohypoparathyroidism (PHP). This is a heterogeneous group of very 
rare endocrine disorders, primarily due to resistance to the parathyroid hor-
mone (PTH) [91]. It was first described by Fuller Albright in 1942 to describe 
patients with PTH-resistant hypocalcaemia and hypophosphatemia and a con-
stellation of skeletal defects called Albright hereditary osteodystrophy (AHO). 
Features of AHO (seen in PHP-1a and -1c) include short stature, stocky built, 
rounded face, short fourth metacarpal and other bones of the hands and feet, 
and ectopic ossifications.
Gene encoding the alpha-subunit of the stimulatory G protein (GNAS1) is 
defective resulting in at least 4 different forms of PHP: PHP-1 a, b, and c, and 
PPHP (pseudo pseudohypoparathyroidism). Molecular defect in PHP-2 is yet 
to be identified. The exact prevalence of PHP is not known.
6. Cohen syndrome or Pepper syndrome or Cervenka syndrome. This was first 
described by M Michael Cohen Jr. in 1973 in two siblings and one isolated case 
[92]. More than a hundred cases have been identified over the world, with 35 
from Finland [93]
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The phenotype in Finnish patients is homogeneous: non-progressive psy-
chomotor retardation, microcephaly, characteristic facial features, myopia, 
progressive retinochoroidal dystrophy, neutropenia, and cheerful disposition. 
Non-Finnish patients have a confusing phenotype. Affected persons have low 
birth weight but develop abnormal truncal fat distribution in teenage. This is 
an autosomal recessive condition, with mutation in the vacuolar protein sort-
ing 13 homolog B (VPS13B, also called COH1 gene) located on chromosome 
8q. This transmembrane protein is involved in vesicle-mediated intracellular 
protein transport.
7. Other syndromes associated with obesity. Down syndrome (trisomy 21) 
and Turner syndrome (45, X) have been reported to be associated with adult 
obesity [94, 95].
C. Polygenic obesity. More than an hundred polygenic loci harboring genetic 
variants associated with overweight and obesity have been identified [96–98]. 
Polygenic obesity is caused by the cumulative effect of obesogenic environment and 
weight-gain promoting genes. The contribution of a single gene is very small, of 
only a few hundred grams, but the combined effect of many such genes in a person 
can have a significant effect on weight gain. Khera et al. [98] have derived and 
validated a polygenic predictor of weight gain.
3.1.2 Epigenetic causes of obesity
Although the DNA in every cell of the multicellular organism is the same 
(exception: mosaicism [99]), the expression of genes is different in different cell 
types. The mechanisms that regulate the expression of genes can be heritable. 
Epigenetic modifications are mitotically and meiotically heritable modulation of 
gene function without changes in the sequence of the DNA [100]. Such modifica-
tions allow or silence the expression of specific genes. Epigenetic programming 
can be influenced by environmental and dietary factors as well as by the gut 
microbiota.
The epigenetic modifications are brought about by DNA methylation (by DNA 
methyltransferases, DNMTs, at distinct CpG sites), histone modification (methyla-
tion, acetylation, ubiquitination, or phosphorylation), and by short non-coding 
RNA species called micro-RNAs or miRNAs.
a. DNA methylation. The CpG sites where methylation occurs are usually present 
in the promoter regions of genes. Addition of methyl group hinders the attach-
ment of transcription factors and represses transcription of the gene. Some 
of these genes are involved in appetite control, obesity, metabolism, insulin 
signaling, inflammation, and growth. Examples of genes associated with obe-
sity having CpG in the promoter regions are the HIF3A, LEP, ADIPOQ, NPY, 
IGF-2, IRS-1, and POMC, etc. Increased methylation of LEP gene was found in 
maternal blood samples with pre-pregnancy obesity and in cord blood samples 
in neonates small for gestational age and whose mothers continued to smoke 
during pregnancy [101]. Tobi et al. [102] reported higher LEP methylation in 
men born after prenatal exposure to wartime (Dutch hunger winter) famine in 
1944–1945 compared to their unexposed same-sex siblings.
b. Histone modification. Histone modifications control the accessibility of the DNA 
to transcription factors. The five key regulatory genes of adipogenesis: pre-adipo-
cyte factor-1 (Pref-1), CCAAT-enhancer-binding protein β (C/EBP β), C/EBPα, 
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PPARγ, and adipocyte protein 2 (aP2), are modulated via histone modification 
during adipocyte differentiation [103].
c. Micro RNA. miRNA are short (18–25 nt) non-coding RNA sequences that 
regulate gene expression [104]. Certain miRNA species have been identified 
that are associated with insulin resistance and low-grade inflammation seen 
in obesity [105]. Childhood obesity is associated with specific miRNAs while 
some miRNAs are associated with weight changes [106–108].
Epigenetic changes influence embryo formation and development, inactivation 
of X chromosome in female, genomic imprinting, cell differentiation, stable inheri-
tance of gene expression, and immune cell function. In case of mice it was observed 
that pregnant animals exposed to polycyclic hydrocarbons during pregnancy 
gave birth to offspring with higher weight and fat mass. These offspring showed 
higher expression of PPAR-γ, C/EBP α, Cox2, FAS and adiponectin and lower DNA 
methylation of PPAR γ. This epigenetic change was heritable, as it was also observed 
in the subsequent generation [109]. Female mice born following perinatal exposure 
to bisphenol A showed significantly different DNA methylated regions compared to 
controls [110].
3.1.3 Maternal factors influencing obesity
Certain factors related to the mother cannot be altered but are known to influ-
ence body weight or metabolic processes of the offspring. A U-shaped association 
between maternal age and fasting glucose concentration in adult offspring has been 
reported [111]. Adult offspring of younger or older mothers had blood glucose 
levels higher by about 0.05 mmol/L higher than the reference group. Early maternal 
menarche [112], maternal diabetes [113], and maternal smoking during pregnancy 
[114] are associated with a higher BMI in offspring. Low maternal education influ-
ences obesity, however, the relationship is different in different ethnicities [115, 
116]. Maternal employment has also been found to influence children’s weight [117].
3.1.4 Hormonal causes of obesity
Secondary obesity (consequence of some other illness) due to endocrine causes 
is relatively less common.
1. Hypothyroidism. Triiodothyronine (T3) and thyroxine (T4) are tyrosine-
derived iodine-containing hormones produced by the thyroid gland that act on 
almost all cells of the body to regulate a variety of metabolic functions. T4 is 
converted to the 4-times more potent T3 by deiodinases in cells, however, since 
T4 has a longer half-life, it is the major form in circulation (ratio of T4/T3 in 
blood is approximately 14).
Weight gain has been reported in thyroid insufficiency. About 54% patients 
with overt hypothyroidism report gain of weight compared to 13.8% control 
subjects [118]. Hypothyroidism is also associated with dyslipidemia with 
increased cholesterol levels. The thyroid gland secretes prohormone thyrox-
ine or T4 (3,5,3′,5′-tetraiodothyronine) along with small quantities of active 
T3 (3,5,3′-triiodothyronine), on receiving the signal from the pituitary gland 
in the form of thyroid stimulating hormone (TSH) or thyrotropin. TSH is re-
leased from the pituitary under the influence of thyrotropin releasing hormone 
(TRH), the master regulator of thyroid function, produced in the paraven-
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tricular nucleus of the hypothalamus. Depending on the underlying cause, 
hypothyroidism can be primary (decreased production of thyroxine by thyroid 
due to various reasons), secondary (due to decreased TSH), tertiary (due to 
deficiency of TRH), and peripheral or consumptive hypothyroidism (due to in-
creased activity of deiodinase 3 which degrades thyroid hormone). Secondary 
and tertiary hypothyroidism are together called central hypothyroidism [119].
Every organ system and cell in the body is influenced directly or indirectly by 
the thyroid hormones. Gut motility, heart rate, body temperature, perfusion 
of lungs, and muscle contraction modulate the effect of catecholamines. In 
females, thyroid hormones influence menstruation, ovulation, and fertility. 
Bone growth and brain maturation in children are also influenced by these hor-
mones, while in adults they affect the mood [120]. Thyroid hormones regulate 
the basal metabolic rate (BMR) and therefore are responsible for increase/de-
crease/maintenance of body weight.
Decreased thyroxine levels cause accumulation of hyaluronic acid in the dermis 
which causes water retention and non-pitting edema [121]. Decreased blood 
flow to kidneys resulting in lowered glomerular filtration rate in hypothyroid-
ism causes water retention and increase in body weight [122]. This is aided by 
decreased tubular resorption and secretion in thyroxine deficiency. Thyroid 
hormones also regulate the number of adrenergic receptors and dopaminergic 
activation of the tubular cells, thus affecting the renin-angiotensin-aldosterone 
(RAA) axis [123].
Hypothyroidism has been shown to cause decreased mitochondrial biogenesis 
and decreased levels of uncoupler proteins [124, 125].
Thyroid dysfunction has been associated with decreased insulin sensitivity 
[126]. This may be a consequence of increased adipose deposition from de-
creased BMR. Increased adipose tissue is known to cause insulin resistance in 
obese subjects.
2. Polycystic Ovarian Syndrome (PCOS). This is a heterogeneous disorder with 
ovarian dysfunction, hirsutism, hyperandrogenism, obesity, and insulin resis-
tance. PCOS has multifactorial etiology with both genetic and environmental 
components [127]. More than 50% of adult women with PCOS are overweight 
or obese and weight reduction alleviates menstrual irregularity [128]. Weight 
deposition is more around the waist (android pattern of fat distribution), and 
is both the cause as well as effect of hyperandrogenaemia [129]. Increased 
adipose tissue leads to higher production of adipokines. Abnormally high 
leptin levels have been noted in PCOS [130], although some authors report that 
the serum levels of leptin correlate with obesity rather than with PCOS [131]. 
Houjeghani et al. have reported higher levels of insulin, testosterone, lutein-
izing hormone (LH), and higher LH to FSH (follicle stimulating hormone) 
ratio in women with PCOS compared to normal age and BMI matched controls 
[132]. Lower concentrations of sex hormone binding globulins were reported 
in PCOS.
3. Cushing Syndrome. The corticosteroid hormones produced by the adrenal 
cortex are of two types: glucocorticoids and mineralocorticoids. The glucocor-
ticoids e.g., cortisol affect metabolism of carbohydrates, fats, and proteins, 
and are involved in anti-inflammation, immunosuppressive, anti-proliferative, 
and vasoconstrictive processes. The mineralocorticoids like aldosterone are 
involved in regulation of water and electrolyte balance.
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All conditions in which cortisol level is higher than normal are classified under 
Cushing syndrome, while Cushing disease is pituitary dependent [133]. Cush-
ing syndrome can be classified into ACTH-dependent, ACTH-independent, 
and pseudo-Cushing syndrome. Cushing disease, ectopic ACTH syndrome, ec-
topic CRH syndrome, macronodular adrenal hyperplasia, and iatrogenic treat-
ment with ACTH are included in the ACTH-dependent variety of Cushing syn-
drome. The ACTH-independent Cushing syndrome includes adrenal adenoma 
and carcinoma, primary pigmented adrenal nodular hyperplasia and Carney’s 
syndrome, McCune-Albright syndrome, aberrant receptor expression, and iat-
rogenic Cushing caused by pharmacotherapy by steroids. Chronic alcoholism 
and depression can cause pseudo-Cushing syndrome. A rare condition with 
repeated episodes of cortisol excess interspersed by regular or irregular periods 
of normal cortisol secretion is called the cyclic Cushing syndrome.
Chronically elevated levels of cortisol in Cushing’s syndrome cause redistribu-
tion of fat and central obesity [133]. Glucocorticoids (GCs) increase hypotha-
lamic endocannabinoids, hypothalamic AMPK activity, and gene expression 
of orexigenic NPY and agouti-related peptide, resulting in increased appetite. 
GCs promote adipocyte differentiation and sensitize preadipocytes to insulin. 
Visceral adipose tissue (VAT) shows differential response to GCs: increased 
deposition and insulin resistance occurs in VAT compared to subcutaneous 
adipose tissue (SAT). Excess glucocorticoids also produce hyperglycemia, dys-
lipidemia, and increased protein degradation.
4. Growth Hormone Deficiency. Growth hormone (GH) or somatotropin exists 
as several isoforms; the major isoform is a 191 amino acid protein. Secretion 
of growth hormone by the somatotropic cells of anterior pituitary is under 
control of the cells of neurosecretory nuclei of hypothalamus, which release 
GH releasing hormone (GHRH) or somatocrinin and GH inhibiting hormone 
(GHIH) or somatostatin. Release of GHRH and GHIH is influenced by physi-
ologic stimulators: sleep, exercise, and nutrition, and by the level of free fatty 
acids in blood. GH is released in a pulsatile manner, the peak occurs an hour af-
ter the onset of sleep. During the day, secretion of GH occurs at 3–5 h intervals 
[134]. Age, sex, diet, exercise, and stress influence GH secretion, which is also 
influenced by the other hormones.
Congenital, acquired, or idiopathic deficiency of GH may be associated with 
increased adipose deposition, especially in the waist region, and insulin resis-
tance. However, reduced GH levels have been reported in some patients with 
obesity [135, 136]. Usually, deficiency of GH in children is due to insufficient 
production of growth hormone releasing hormone in the hypothalamus. Dam-
age to the pituitary or hypothalamus (due to tumor or tumor-related surgery, 
stroke, bleeding, infection, etc) in adulthood may lead to decreased GH pro-
duction. GH increases lipolysis in the adipose tissue, and reduces storage of TG 
in a non-uniform manner. Thus it promotes loss of intra-abdominal fat. Scacchi 
et al. [137] reported that a primary growth hormone deficiency causes centrip-
etal adiposity, while obesity with increase in visceral adipose tissue produces 
secondary growth hormone deficiency.
5. Laron syndrome or primary growth hormone insensitivity (GHI). GHI 
[138] is a group of rare disorders caused by mutations either in the GH recep-
tor gene, or in genes of signaling proteins within the cell that are activated on 
binding of GH to its receptor. Various mutations and their effects have been 
summarized by Boro et al. [139]. Synthesis of insulin-like growth factor (IGF)-
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1 is prevented although GH levels in blood are normal or high. Such children 
show improved growth when IGF-1 is administered before puberty, but no 
improvement if only GH treatment is given. Children with GHI show delayed 
onset of puberty, short limbs, reduced muscle strength and endurance, promi-
nent forehead, low blood sugar, and obesity in adulthood.
6. Ghrelin (Lenomorelin). Ghrelin is a 28 amino acid peptide hormone dis-
covered in 1999 by Kojima et al. [140]. It is a fast-acting orexigenic hormone 
produced by the endocrine cells (ghrelin cells) in gastric fundus and to a lesser 
extent in the body of the stomach, intestinal mucosa, lungs, urogenital organs, 
and brain. It has a role in meal initiation. Pre-prandial ghrelin surges occur at 
fixed feeding schedules, or at food-related cues. The post-prandial decrease in 
ghrelin levels is due to increased intestinal osmolarity and increased insulin. 
Ghrelin regulates the input and output of calories, and therefore influences the 
body weight, via the G-protein-coupled growth hormone secretagogue recep-
tor (GHSR)1a. Besides regulating appetite, ghrelin stimulates secretion of GH 
and ACTH, increases gut motility and gastric acid secretion, modulates sleep, 
stress, and anxiety, influences taste sensation and reward-seeking behavior, 
regulates glucose metabolism, reduces lipid degradation, and suppresses ther-
mogenesis in brown adipose tissue. It has been shown to protect muscle from 
atrophy and improve cardiovascular function [141].
Two distinct forms of ghrelin are present in blood: acylated ghrelin (AG) and 
unacylated ghrelin (UAG). About 90% of the circulating ghrelin in unacylated 
(UAG). The AG acts on GHSR 1a mediating growth hormone release, while 
UAG acts on GHSR 1a on pancreatic cells stimulating the release of insulin and 
glucose utilization. AG opposes the action of UAG, inhibiting the release of 
insulin. In obesity, UAG levels decrease while the AG levels remain unchanged.
Highest levels of ghrelin in blood are immediately before a meal, and drop to low-
est levels immediately after the meal. Ghrelin administration increases appetite in 
both humans and rats. Ghrelin and synthetic ghrelin mimetics bind to the GHSR1a 
in hypothalamus, brain stem, and in the mesolimbic pathway, cause secretion of 
orexigenic neuropeptide Y (NPY) and agouti-related protein (AgRP). GHSR 1a 
is also expressed in vagal efferent neurons. Under influence of ghrelin, the gastric 
vagal efferents become less sensitive to gastric distension, increasing food intake.
Plasma level of ghrelin is lower in persons with obesity, except in patients 
with Prader-Willi syndrome, where ghrelin levels are proportional to the food 
intake. AG and UAG levels were compared in insulin-resistant and insulin-
sensitive subjects with obesity. It was found that UAG and total ghrelin was 
lowered in insulin-resistant subjects, while only AG levels were lowered in the 
insulin-sensitive subjects [142]. In patients with anorexia nervosa and with 
cancer-induced cachexia, ghrelin levels are high [143, 144]. Obese rodents with 
low levels of ghrelin in plasma have reduced levels of ghrelin-receptor mRNA 
as compared to the normal lean controls. Experiments on rodents showed that 
central ghrelin signaling activates reward centres in response to alcohol, food, 
high-fat diet, and psychosomatic drugs like cocaine [145, 146].
Besides being the hunger signal, the ghrelin-GHSR 1a system is related to the 
rewarding aspects of food intake. It is activated in anticipation of food intake, 
negative energy balance, and psychological stress. In times of food scarcity, the 
effect of the ghrelin/GHSR 1a system on the mesolimbic pathway is advanta-
geous for the animal’s survival.
17
The Multiple Causes of Obesity
DOI: http://dx.doi.org/10.5772/intechopen.98835
In developed countries, as well as in the rapidly developing countries, the 
changes in environment are favoring sedentary lifestyle, easy availability of 
calorie-dense tasty affordable foods, and increased stress levels are promoting 
increased appetite. The action of ghrelin on the mesolimbic system increases 
the appetite, acting as a spice to further increase food intake. In the current 
scenario of easy availability of food, the ghrelin/GHSR 1a system is no longer 
an evolutionary advantage but is in part responsible for the obesity epidemic 
and the associated diseases [147].
Weight gain may also be influenced by insulin, estrogen, progesterone, prolac-
tin, and melatonin.
3.2 Exogenous causes of obesity
Certain factors that are preventable and influence the person from outside the 
body are classified as exogenous causes.
3.2.1 Depression, sleep deprivation, gut microbiota, and infections
1. Depression. Previously it was believed that depression was associated with a 
loss of appetite and sleep, with an inability to persuade oneself to cheer up and 
get going. Later, atypical depression was noted for increased eating, hyper-
somnia, frequent, relatively short episodes, and a proclivity to obesity [148]. 
Murphy et al. [149] reported that many patients with depression felt like eating 
when they felt bad. From their study on 1396 subjects, they concluded that 
patients with obesity tended to experience more severe depression, compared 
to the non-obese. It is possible that the stigma of obesity contributed to the 
depression.
2. Sleep deprivation. Lack of sufficient sleep has been reported to be associated 
with high fat intake, night-time snacking, binge-eating, and gain of weight 
[150]. Altered sleep patterns due to shift work, trans-continental travel, sleep 
apnoea, or due to new parenthood can lead to sleep insufficiency. Sleep restric-
tion causes increased fat and carbohydrate intake and increased intake of total 
calories, with no corresponding increase in energy expenditure. Ding et al. 
[151] note that sleep dysregulation perturbs appetite-regulating hormones like 
leptin and ghrelin, affecting eating behavior and metabolism.
3. Gut microbiota (GM). Ninety-nine percent of the gut microbiota are bacte-
ria, of which 90% are of the phyla Firmicutes and Bacteroidetes [152]. Some 
fungal, protozoan, and archaeal species have also been isolated. Some bacteria 
belong to the phyla Proteobacteria, Actinobacteria, Verrucomicrobia, and Fu-
sobacteria. Most GM share a commensal relationship with the host, enhancing 
the overall fitness. A 20% increase in Firmicutes and a corresponding decrease 
in Bacteroidetes is associated with the increase in energy intake, thus inducing 
obesity. GM composition is involved in diseases like obesity, diabetes, inflam-
matory and immune disorders, and cancer.
Type of food taken influences the population of gut biota. High fat Western 
diet reduces Bacteroidetes and increases in Firmicutes population, similar to 
what is seen in obesity. Increased ratio of Bacteroidetes to Firmicutes is linked 
with diminished body mass. L. rhamnosus and Lactobacillus plantarum are 
probacteria that convert dietary linoleic acid to conjugated linoleic acid (CLA). 
In mice, these bacteria prevent weight gain on a high fat diet. Various probiotic 
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strategies are being developed to tailor the GM in such a way that they can help 
reduce weight of the host. GM are also associated with low-grade inflammation 
and metabolic syndrome via endotoxemia [153].
4. Viral infections. Four animal (canine distemper virus, Rous-associated virus 
type 7, Borna disease virus, and SMAM-1) and three human viruses (adenovi-
rus (Ad) 36, Ad-37, and Ad-5) are known to cause obesity [154]. Scrapie agent 
has been shown to produce obesity in mice [155]. The infection affects fat cell 
differentiation, modulates appetite, or cause inflammation that dysregulates 
the feeding centre of the brain [156]. SMAM-1 is an avian adenovirus that is 
associated with human obesity. The human viruses stimulate enzymes and 
transcription factors that cause differentiation of preadipocytes into mature 
adipocytes and accumulation of TAGs.
3.2.2 Obesogenic environment
1. Sedentary lifestyle and neighborhood safety. Rapid urbanization has 
brought about various energy-saving techniques that promote sedentary 
lifestyle: convenient and cheap motorized transport, elevators, household ap-
pliances, etc. Entertainment is available 24 x 7, on the television or the mobile 
phone. Instead of playing games in the fields, children and adults prefer to play 
video games on a comfortable couch. Built environment, especially in areas 
inhabited by people with low socioeconomic status, is devoid of safe parks 
and walkways. Often in unsafe neighborhoods parents prefer their children to 
stay at home rather than venture out in the parks. Physical inactivity results in 
reduced energy expenditure, and if calorie intake is not reduced, it will ulti-
mately lead to weight gain [157, 158].
2. Diet. With the abundance of calorie-dense food in attractive flavors and af-
fordable prices, calorie-intake has increased for many persons. Fast-food is 
available at nearby stalls and it has become easier to purchase ready-to-eat food 
rather than cook at home. With increase in the number of nuclear families and 
double-incomes, home-cooked meals have been replaced by take-aways, home 
deliveries, and restaurant dinners. Calorie, carbohydrate, fat, and salt intake 
has increased, while intake of fruits and vegetables has decreased. Sweetened 
beverages and alcohol add empty calories [159, 160].
3. Socioeconomic status (SES). In case of developed countries, the incidence of 
obesity decreases with increased income and education [161], as people enjoy 
food security, are aware of healthy choices, and can afford healthy lifestyles 
in socially secure neighborhoods. In developing countries, the situation is 
complex. Low SES is associated with lack of food and medicines, ignorance 
regarding health, hygiene, and family size, and unwillingness to change 
[162]. An increase in family income brings about weight gain that can exceed 
the healthy limit. This is promoted by food insecurity. High SES shows slight 
decrease in obesity, however, this may not hold true for obesity in children, 
as high purchasing power and lack of self-control may lead to splurging on 
unhealthy foods.
4. Unhealthy food advertisements. Many people, especially children, are sus-
ceptible to food advertisements [163]. Aggressive marketing of calorie-dense 
food, sweetened beverages, cereals, snacks, etc. on the television, in print, on 
hoardings, and in shops affects vulnerable people. The message is clear: eat to 
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feel good. Many adults, especially those prone to depression, are affected in the 
same manner as children. Children who are overweight or obese usually grow 
into adults with weight issues.
5. Culture and Ethnicity. Certain cultures prefer chubbiness in children and 
adults and consider it a sign of health [164]. In Asian cultures, hospitality and 
affection are demonstrated through food. Asian men and women are more 
prone to develop central obesity [165]. Reward eating also promotes intake of 
unrequired calories in the form of high fat/high sucrose foods.
6. Endocrine Disrupting Chemicals (EDCs). The endocrine disrupting chemi-
cals are man-made chemicals that block connections between hormones and 
their receptors [166]. The number of EDCs in the environment is increasing 
rapidly, even though their use has been banned. Their role in obesity has been 
highlighted by Brown et al. [167], who have used the U.S. National Health and 
Nutrition Examination Survey data, collected over nearly 4 decades, showing 
increase in calorie intake and BMI over time. For a given amount of calorie and 
macronutrient intake and leisure-time physical activity, the predicted BMI was 
significantly higher in 2006 than in 1998, indicating that factors other than 
diet and physical activity are contributing to the weight gain.
More than 800 EDCs have been identified [168]. Persistent organic pollutants 
(POPs) and certain heavy metals have been classified into EDCs, metabolism 
disrupting chemicals (MDCs), and mitochondrial function disrupting chemicals 
(MtDCs). They can interact with nuclear and mitochondrial genes and bring 
about epigenetic changes, decrease insulin sensitivity, promote inflammation and 
obesity, decrease basal metabolic rate (BMR), and narrow down the vasculature.
EDCs may be classified into obesogens and diabetogens. The obesogens (e.g. 
tributyltin, bisphenol A, phthalates, and metals like arsenic) can increase adi-
pocyte differentiation and adipose tissue depots, disrupt normal lipid metabo-
lism leading to obesity. The compound atrazine inhibits the electron transport 
chain in the mitochondrion. It has been shown to decrease BMR. Diabetogens 
either destroy beta cells of pancreas or disrupt their function leading to diabe-
tes [169]. Bisphenol A blocks insulin receptor site causing insulin resistance.
7. Weight-gain caused by pharmacotherapy. Certain drugs can lead to weight 
gain or redistribution of fat. Large increase in weight may be accompanied by 
dyslipidemia, insulin resistance, metabolic syndrome, and increased risk of 
type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), CVD, and cancer. 
Drugs associated with weight gain are described below.
a. Antidepressants. Drugs causing up to 5 kilogram per year weight gain include 
the following:
Tricyclic agents like amitriptyline and doxepine.
Selective serotonin reuptake inhibitors (SSRIs) like paroxetine and citalopram.
Serotonin and norepinephrine uptake inhibitors (SNRIs) like venlafaxine and 
duloxetine.
Monoamine oxidase inhibitors (MAOIs) like moclobemide, phenelzine.
Others like mirtazapine, mianserine, and maprotiline.
Bupropion is a norepinephrine and dopamine reuptake inhibitor that reduces 
food cravings. In US bupropion and naltrexone combination has been approved as 
an anti-obesity drug.
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b. Mood Stabilizer. Lithium used in the treatment of bipolar disorders causes a 
weight gain of more than 5% of the initial body weight.
c. Antipsychotics. Typical antipsychotics like haloperidol and perphenazine 
cause weight gain of up to 5 kg/year. Some atypical antipsychotics like clo-
zapine and olanzapine can cause more than 5 kilogram weight gain in a year 
(4.5–16.2 kg/year). Atypical antipsychotics like amisulpiride, quietapine, and 
sertindole cause weight gain of up to 5 kg/year.
d. Anticonvulsants. Topiramate and zonisamide produce weight loss. 
Gabapentine and pregabalin cause weight gain of up to 5 kg/year. Valproate and 
carbamazepine cause weight gain of more than 5 kg/year [170].
e. Antihyperglycemics. Type2 diabetes is strongly associated with diabetes. 
Many of the drugs used in the treatment can cause weight gain. Insulin, meg-
litinides, and sulfonylureas are known to cause weigh gain. Sulfonylureas like 
glimepiride, glyburide, glibenclamide, and gliclazide) and meglitinides (e.g. 
repaglinide) stimulate insulin secretion from the pancreas. Thiazolidinediones 
(TZD) or glitazones (e.g. pioglitazone) improve insulin sensitivity by acting 
on transcription factor PPAR-γ, which is involved in glucose and fat oxidation. 
Insulin increases lipogenesis and fat storage resulting in weight gain [171].
f. Antihypertensives. Weight gain is often associated with hypertension, and 
certain medicines used in the treatment of hypertension can cause weight gain. 
These include beta-blockers (atenolol, propranolol), angiotensin receptor 
blocker valsartan, and calcium channel blocker diltiazem [172].
g. Corticosteroids. Although short-term use of corticosteroids is not associated 
with significant change of weight, long-term use (> 3 months) is associated 
with significant gain of weight. Some patients showed a weight gain of >10 kg/
year with prednisone [173].
Since many of the patients are already struggling with the problem of overweight or 
obesity, it is important to prescribe drugs that are weight neutral or promote weight loss.
4. Direction of future research
The obesity pandemic has spread across the globe and a lot of research is being 
done regarding its control. If the cause of obesity is known, it is easier to cure 
or limit the disease. Most of the current research is related to diagnosis of the 
underlying causes of the condition, as removal of the cause can ameliorate the 
condition. Suitable lifestyle changes and pharmacotherapies are being designed to 
reduce weight. Different types of surgical interventions have been improvised to 
stop weight gain/promote weight loss in patients with severe obesity.
5. Conclusion
Obesity prevalence is increasing worldwide to assume pandemic proportions. 
Since many diseases are associated with obesity, it is important to identify the pres-
ence and causes behind overweight and obesity. We have attempted to list the various 
causes behind obesity, but we may have missed out some inadvertently or due to lack 
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of space. The purpose behind this work is to generate awareness about how overweight 
and obesity are sometimes beyond the patient’s control. People with obesity of all ages 
have to face discrimination in the society, teaching institutes, and at the workplace. 
Often this discrimination leads to depression, stress, and overeating and aggravates 
the problem. It is important to remove this stigma and to consider people who are 
having to deal with this stigma as victims, rather than justifying the discrimination.
The World Health Organization has recognized obesity as a disease. It is impor-
tant for physicians and healthcare workers to treat patients with obesity with com-
passion and empathy, to be open to endogenous and exogenous causes of obesity, and 
to suggest weight loss remedies if the patient is unable to achieve it himself/herself.
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